Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study

Background We aimed to estimate XBB.1.5 vaccine effectiveness (VE) against COVID-19-related hospitalizations and deaths during BA.2.86/JN.1 predominance, among EU/EEA individuals with ≥65-years.Research design and methods We linked electronic health records to create historical cohorts in Belgium, D...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Expert Review of Vaccines
المؤلفون الرئيسيون:	Baltazar Nunes, James Humphreys, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Ida Rask Moustsen-Helms, Chiara Sacco, Massimo Fabiani, Jesús Castilla, Iván Martínez-Baz, Hinta Meijerink, Ausenda Machado, Patricia Soares, Rickard Ljung, Nicklas Pihlström, Anthony Nardone, Sabrina Bacci, Susana Monge
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Taylor & Francis Group 2024-12-01
الموضوعات:	COVID-19 SARS-CoV-2 vaccine effectiveness hospitalization cohort design electronic health records
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/14760584.2024.2428800

مواد مشابهة

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
حسب: Juleen Gayed, وآخرون
منشور في: (2024-07-01)

Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data
حسب: Anders Hviid, وآخرون
منشور في: (2024-08-01)

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion
حسب: Delphine Planas, وآخرون
منشور في: (2024-03-01)

Severity of COVID-19 sub-lineages XBB/XBB 1.5/XBB1.16, EG.5.1. and JN.1. in England
حسب: Catherine Quinot, وآخرون
منشور في: (2024-08-01)

XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies
حسب: Juan Manuel Carreño, وآخرون
منشور في: (2025-04-01)

Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1, and JN.1 six months after the BNT162b2 bivalent booster
حسب: Julien Favresse, وآخرون
منشور في: (2024-06-01)

Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine
حسب: Xammy Huu Nguyenla, وآخرون
منشور في: (2024-06-01)

An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters
حسب: Ryuta Uraki, وآخرون
منشور في: (2025-02-01)

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
حسب: Hui Zhao, وآخرون
منشور في: (2024-01-01)

Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis
حسب: Eliel Nham, وآخرون
منشور في: (2024-05-01)

Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients
حسب: Philippa von der Schulenburg, وآخرون
منشور في: (2024-12-01)

Immune imprinting and vaccine interval determine antibody responses to monovalent XBB.1.5 COVID-19 vaccination
حسب: Xammy Huu Wrynla, وآخرون
منشور في: (2025-05-01)

Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants
حسب: Hong Lei, وآخرون
منشور في: (2024-11-01)

T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects
حسب: Irene Segato, وآخرون
منشور في: (2024-12-01)

Evolution of SARS-CoV-2 from BA.2.86 to JN.1 variations and detection in Bangladesh
حسب: Miah Roney, وآخرون
منشور في: (2024-08-01)

Analysis of B‐cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines
حسب: Yohei Funakoshi, وآخرون
منشور في: (2024-08-01)

Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants
حسب: Haonan Yang, وآخرون
منشور في: (2024-09-01)

Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage
حسب: Joseph A. Lewnard, وآخرون
منشور في: (2024-10-01)

15 Divergent performance of bivalent BA.5 and monovalent XBB.1.5 COVID-19 vaccines given as annual booster
حسب: Marianne Shawe-taylor, وآخرون
منشور في: (2025-03-01)

Monovalent XBB.1.5 booster vaccination induces a broad spectrum of SARS-CoV-2 neutralizing antibodies
حسب: Nan Huo, وآخرون
منشور في: (2024-12-01)

Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages
حسب: Jingyun Yang, وآخرون
منشور في: (2025-01-01)

A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants
حسب: Jingyun Yang, وآخرون
منشور في: (2025-02-01)

XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants
حسب: Matthew E. Levy, وآخرون
منشور في: (2025-02-01)

Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1
حسب: Hisano Yajima, وآخرون
منشور في: (2024-10-01)

Systemic and Mucosal Immunogenicity of Monovalent XBB.1.5-Adapted COVID-19 mRNA Vaccines in Patients with Inflammatory Bowel Disease
حسب: Simon Woelfel, وآخرون
منشور في: (2024-07-01)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
حسب: Yanping Hu, وآخرون
منشور في: (2023-12-01)

Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials
حسب: Jingyun Yang, وآخرون
منشور في: (2024-12-01)

Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1
حسب: Muhammad Saqib Sohail, وآخرون
منشور في: (2024-03-01)

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH)
حسب: Maxim Cherneha, وآخرون
منشور في: (2024-07-01)

Vegetation ecological benefits index (VEBI): a 3D spatial model for evaluating the ecological benefits of vegetation
حسب: Zhimei Zhang, وآخرون
منشور في: (2023-12-01)

Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies
حسب: Xun Wang, وآخرون
منشور في: (2024-05-01)

Lessons from COVID‐19: Aspects of prevention, therapeutics, and diagnostics against SARS‐CoV‐2 with special focus on JN.1 and XBB sublineages
حسب: Puja Jaishwal, وآخرون
منشور في: (2024-06-01)

Predicting antibody and ACE2 affinity for SARS-CoV-2 BA.2.86 and JN.1 with in silico protein modeling and docking
حسب: Shirish Yasa, وآخرون
منشور في: (2024-07-01)

Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2
حسب: Shuhei Tsujino, وآخرون
منشور في: (2025-10-01)

Comparative analysis of replication and immune evasion among SARS-CoV-2 subvariants BA.2.86, JN.1, KP.2, and KP.3
حسب: Yanping Hu, وآخرون
منشور في: (2025-06-01)

Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3
حسب: Yuanchen Liu, وآخرون
منشور في: (2024-10-01)

Durability of protection of ancestral-strain COVID-19 third- and fourth-dose vaccine boosters against Omicron XBB/XBB.1 and JN.1 symptomatic infection, hospitalisation and mortality in Indonesian adults (2023–2024): a test-negative case–control studyResearch in context
حسب: Bayu Satria Wiratama, وآخرون
منشور في: (2025-11-01)

An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variantResearch in context
حسب: Ryuta Uraki, وآخرون
منشور في: (2025-07-01)

SARS‐CoV‐2 Omicron subvariants from BA.2 to BA.2.86 and JN.1: strong lung infection ability and evolving immune escape capacity
حسب: Bixia Hong, وآخرون
منشور في: (2024-07-01)

Rapid spread of the SARS-CoV-2 Omicron XDR lineage derived from recombination between XBB and BA.2.86 subvariants circulating in Brazil in late 2023
حسب: Ighor Arantes, وآخرون
منشور في: (2025-01-01)